Zhaohua Richard Huang

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 5

Top Topics

Epithelial Mesenchymal Transition

Top Venues

Molecular pharmaceutics

Nature biomedical engineering

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Sheryl Wang, Hong Wang, Andrew Drabek, Wenwen Sha Smith, Feng Liang, Zhaohua Richard Huang
Unleashing the Potential: Designing Antibody-Targeted Lipid Nanoparticles for Industrial Applications with CMC Considerations and Clinical Outlook. Molecular pharmaceutics (2023)
Sheryl Wang, Hong Wang, Andrew Drabek, Wenwen Sha Smith, Feng Liang, Zhaohua Richard Huang
Unleashing the Potential: Designing Antibody-Targeted Lipid Nanoparticles for Industrial Applications with CMC Considerations and Clinical Outlook. Molecular pharmaceutics 21 (1) (2023)
Sheryl Wang, Hong Wang, Andrew Drabek, Wenwen Sha Smith, Feng Liang, Zhaohua Richard Huang
Unleashing the Potential: Designing Antibody-Targeted Lipid Nanoparticles for Industrial Applications with CMC Considerations and Clinical Outlook. Molecular pharmaceutics 21 (1) (2023)
Walid S Kamoun, Anne-Sophie Dugast, James J Suchy, Stephanie Grabow, Ross B Fulton, James F Sampson, Lia Luus, Michael Santiago, Alexander Koshkaryev, Gang Sun, Vasileios Askoxylakis, Eric M Tam, Zhaohua Richard Huang, Daryl C Drummond, Andrew J Sawyer
Synergy between EphA2-ILs-DTXp, a Novel EphA2-Targeted Nanoliposomal Taxane, and PD-1 Inhibitors in Preclinical Tumor Models. Molecular cancer therapeutics 19 (1) (2019)
Walid S Kamoun, Dmitri B Kirpotin, Zhaohua Richard Huang, Suresh K Tipparaju, Charles O Noble, Mark E Hayes, Lia Luus, Alexander Koshkaryev, Jaeyeon Kim, Ken Olivier, Tad Kornaga, Shinji Oyama, Vasileios Askoxylakis, Christine Pien, Geoffrey Kuesters, Nancy Dumont, Alexey A Lugovskoy, Sarah A Schihl, John H Wilton, Melissa L Geddie, James Suchy, Stephanie Grabow, Neeraj Kohli, C Patrick Reynolds, Rachel Blaydes, Yu Zhou, Andrew J Sawyer, James D Marks, Daryl C Drummond
Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models. Nature biomedical engineering 3 (4) (2019)